Hairy cell leukemia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Hairy cell leukemia}} | {{Hairy cell leukemia}} | ||
{{CMG}} | {{CMG}} | ||
Line 4: | Line 5: | ||
==Overview== | ==Overview== | ||
== | ==Future or Investigational Therapies== | ||
* Three immunotoxin drugs are in Phase II trials at the [[NIH]]'s [[National Cancer Institute]] in the U.S.: [[BL22]]<ref>{{ClinicalTrials|NCT00074048}}</ref>, HA22<ref>{{ClinicalTrials|NCT00462189}}</ref> and LMB-2.<ref>{{ClinicalTrials|NCT00337311}}</ref> | |||
All three of these therapies are available only at the National Cancer Institute in Bethesda, Maryland, USA. While initial results are generally favorable, it is likely to be a number of years before these drugs are available on the market. | * All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with HCL-classic or the Japanese variant. | ||
* All three of these therapies are available only at the National Cancer Institute in Bethesda, Maryland, USA. While initial results are generally favorable, it is likely to be a number of years before these drugs are available on the market. | |||
==References== | ==References== | ||
Line 16: | Line 18: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] |
Revision as of 14:42, 17 September 2012
Hairy cell leukemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hairy cell leukemia future or investigational therapies On the Web |
American Roentgen Ray Society Images of Hairy cell leukemia future or investigational therapies |
FDA on Hairy cell leukemia future or investigational therapies |
CDC on Hairy cell leukemia future or investigational therapies |
Hairy cell leukemia future or investigational therapies in the news |
Blogs on Hairy cell leukemia future or investigational therapies |
Risk calculators and risk factors for Hairy cell leukemia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
- Three immunotoxin drugs are in Phase II trials at the NIH's National Cancer Institute in the U.S.: BL22[1], HA22[2] and LMB-2.[3]
- All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with HCL-classic or the Japanese variant.
- All three of these therapies are available only at the National Cancer Institute in Bethesda, Maryland, USA. While initial results are generally favorable, it is likely to be a number of years before these drugs are available on the market.